Drug Safety

2012 - 2025

Current editor(s): Nitin Joshi

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 40, issue 12, 2017

Is Ribavirin Teratogenic in Humans? No Evidence So Far pp. 1163-1165

Vicente Soriano and Pablo Barreiro

Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient? pp. 1167-1170

Rebecca E. Chandler

Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review pp. 1171-1198

Samuel Deshayes, Antoine Coquerel and Renaud Verdon

Commercial Online Social Network Data and Statin Side-Effect Surveillance: A Pilot Observational Study of Aggregate Mentions on Facebook pp. 1199-1204

Marco D. Huesch

The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment pp. 1205-1218

Susan M. Sinclair, Judith K. Jones, Richard K. Miller, Michael F. Greene, Paul Y. Kwo and Willis C. Maddrey

Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan pp. 1219-1229

Kazuki Ozawa, Akiyo Hineno, Tomomi Kinoshita, Sakiko Ishihara and Shu-ichi Ikeda

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience pp. 1231-1240

Helena Gama, Mariana Vieira, Raquel Costa, Joana Graça, Luís M. Magalhães and Patrício Soares-da-Silva

Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance pp. 1241-1248

Victoria Newbould, Steven Meur, Thomas Goedecke and Xavier Kurz

Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase pp. 1249-1258

Emilie Patras Campaigno, Inès Kebir, Jean-Louis Montastruc, Manuela Rueter, Delphine Maret, Maryse Lapeyre-Mestre, Brigitte Sallerin and Fabien Despas

A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients pp. 1259-1277

Andrew M. Tomlin, David M. Reith, David J. Woods, Hywel S. Lloyd, Alesha Smith, John S. Fountain and Murray W. Tilyard

Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications pp. 1279-1292

Rachel B. Weinstein, Patrick Ryan, Jesse A. Berlin, Amy Matcho, Martijn Schuemie, Joel Swerdel, Kayur Patel and Daniel Fife

Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance pp. 1293-1293

Victoria Newbould, Steven Meur, Thomas Goedecke and Xavier Kurz

Correction to: Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient? pp. 1295-1295

Rebecca E. Chandler

Volume 40, issue 11, 2017

Pharmacovigilance Using Textual Data: The Need to Go Deeper and Wider into the Con(text) pp. 1047-1048

Tavpritesh Sethi and Nigam H. Shah

Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury pp. 1049-1074

Sandra L. Kane-Gill, Pamela L. Smithburger, Kianoush Kashani, John A. Kellum and Erin Frazee

Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review pp. 1075-1089

Yuan Luo, William K. Thompson, Timothy M. Herr, Zexian Zeng, Mark A. Berendsen, Siddhartha R. Jonnalagadda, Matthew B. Carson and Justin Starren

Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs pp. 1091-1098

Ipek Celikyurt, Christoph R. Meier, Michael Kühne and Beat Schaer

Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database pp. 1099-1107

Cécile Pageot, Julien Bezin, Andy Smith, Mickael Arnaud, Francesco Salvo, Françoise Haramburu, Bernard Bégaud and Antoine Pariente

Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case–Control Study in South Korea pp. 1109-1118

Hae-Young Park, Ji-Won Park, Hyun Soon Sohn and Jin-Won Kwon

Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance pp. 1119-1129

Rolina D. van Gaalen, Michal Abrahamowicz and David L. Buckeridge

Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System pp. 1131-1140

Paola Maria Cutroneo, Claudia Giardina, Valentina Ientile, Simona Potenza, Laura Sottosanti, Carmen Ferrajolo, Costantino J. Trombetta and Gianluca Trifirò

Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database pp. 1141-1146

Takamasa Sakai, Fumiko Ohtsu, Chiyo Mori, Kouichi Tanabe and Nobuyuki Goto

The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study pp. 1147-1155

Meital Shlomo, Rafael Gorodischer, Sharon Daniel, Arnon Wiznitzer, Ilan Matok, Boris Fishman, Gideon Koren and Amalia Levy

Volume 40, issue 10, 2017

The New Phase of ISoP pp. 841-844

Sten Olsson, Ian C. K. Wong, Jean-Christophe Delumeau and Mira Harrison-Woolrych

A New Erice Report Considering the Safety of Medicines in the 21st Century pp. 845-849

Ivor Ralph Edwards

Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke pp. 851-853

Matilda Florentin and Moses S. Elisaf

Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works pp. 855-869

Aniello Santoro, Georgy Genov, Almath Spooner, June Raine and Peter Arlett

Frequency and Nature of Medication Errors and Adverse Drug Events in Mental Health Hospitals: a Systematic Review pp. 871-886

Ghadah H. Alshehri, Richard N. Keers and Darren M. Ashcroft

Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study pp. 887-893

Kieran L. Quinn, Erin M. Macdonald, Muhammad M. Mamdani, Christina Diong and David N. Juurlink

Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database pp. 895-909

Alice Capogrosso Sansone, Irma Convertino, Maria Teresa Galiulo, Stefano Salvadori, Stefania Pieroni, Tamara Knezevic, Stefania Mantarro, Alessandra Marino, Manfred Hauben, Corrado Blandizzi and Marco Tuccori

Patients’ Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana pp. 911-921

George Tsey Sabblah, Delese Mimi Darko, Hudu Mogtari, Linda Härmark and Eugène Puijenbroek

Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis pp. 923-932

Katsiaryna Bykov, Sebastian Schneeweiss, Robert J. Glynn, Murray A. Mittleman, David W. Bates and Joshua J. Gagne

Brian A. Baldo, Safety of Biologics Therapy: Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins, 1st Edition, Springer, 2016, Print Book ISBN: 978-3-319-30470-0, e-Book ISBN 978-3-319-30472-4 pp. 933-934

Kevin Broady

Comment on “Patient Reporting in the EU: Analysis of EudraVigilance Data” pp. 935-936

Farid Kheloufi, Anne Default, Frank Rouby, Olivier Blin and Joelle Micallef

Volume 40, issue 9, 2017

Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs pp. 757-760

Malcolm Maclure

Potential Teratogenic Effects of Clomiphene Citrate pp. 761-769

Alessandra Scaparrotta, Francesco Chiarelli and Alberto Verrotti

Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies pp. 771-781

Lauren Hirsch, Jaeun Yang, Lauren Bresee, Nathalie Jette, Scott Patten and Tamara Pringsheim

The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware pp. 783-787

Maricruz Vega, Manisha Verma, David Beswick, Stephanie Bey, Jared Hossack, Nathan Merriman, Ashish Shah and Victor Navarro

Evaluation of the Case–Crossover (CCO) Study Design for Adverse Drug Event Detection pp. 789-798

Zachary Burningham, Tao He, Chia-Chen Teng, Xi Zhou, Jonathan Nebeker and Brian C. Sauer

An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System pp. 799-808

Geetha Iyer, Sathiya Priya Marimuthu, Jodi B. Segal and Sonal Singh

Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People’s Democratic Republic pp. 809-821

Céline Caillet, Chanvilay Sichanh, Gaëtan Assemat, Myriam Malet-Martino, Agnès Sommet, Haleh Bagheri, Noudy Sengxeu, Niphonh Mongkhonmath, Mayfong Mayxay, Lamphone Syhakhang, Maryse Lapeyre-Mestre, Paul N. Newton and Anne Roussin

Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping pp. 823-834

Ippazio Cosimo Antonazzo, Emanuel Raschi, Luca Vignatelli, Elisa Baldin, Trond Riise, Roberto D’Alessandro, Fabrizio De Ponti and Elisabetta Poluzzi

Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study pp. 835-840

Kieran L. Quinn, Erin M. Macdonald, Tara Gomes, Muhammad M. Mamdani, Anjie Huang and David N. Juurlink

Volume 40, issue 8, 2017

Good Intentions, But What About Unintended Consequences? pp. 647-649

Helen C. Kales and Donovan T. Maust

Species Adulteration in the Herbal Trade: Causes, Consequences and Mitigation pp. 651-661

Ramanujam Srirama, J. U. Santhosh Kumar, G. S. Seethapathy, Steven G. Newmaster, S. Ragupathy, K. N. Ganeshaiah, R. Uma Shaanker and Gudasalamani Ravikanth

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis pp. 663-677

Angel Y. S. Wong, Esther W. Chan, Shweta Anand, Alan J. Worsley and Ian C. K. Wong

Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice pp. 679-692

S. Jill Stocks, Evangelos Kontopantelis, Roger T. Webb, Anthony J. Avery, Alistair Burns and Darren M. Ashcroft

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt pp. 693-702

Gaël Dos Santos, Harry A. Seifert, Vincent Bauchau, Vivek Shinde, Dominique M. Barbeau and Catherine Cohet

Detecting Signals of Disproportionate Reporting from Singapore’s Spontaneous Adverse Event Reporting System: An Application of the Sequential Probability Ratio Test pp. 703-713

Cheng Leng Chan, Sowmya Rudrappa, Pei San Ang, Shu Chuen Li and Stephen J. W. Evans

Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM pp. 715-727

Erik Scalfaro, Henk Johan Streefkerk, Michael Merz, Christoph Meier and David Lewis

Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and Preferences pp. 729-742

Sieta T. Vries, Maartje J. M. Sar, Amelia Cupelli, Ilaria Baldelli, Anna Marie Coleman, Dolores Montero, Ivana Šipić, Adriana Andrić, Annika Wennberg, Jane Ahlqvist-Rastad, Petra Denig and Peter G. M. Mol

People’s Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England pp. 743-754

Rebecca K. Webster, John Weinman and G James Rubin

Comment on: “Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts” pp. 755-755

Viroj Wiwanitkit

Volume 40, issue 7, 2017

The Power of the Case Narrative - Can it be Brought to Bear on Duplicate Detection? pp. 543-546

G. Niklas Norén

Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches pp. 547-558

Guillermo Prada-Ramallal, Bahi Takkouche and Adolfo Figueiras

Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations pp. 559-570

Diego Bagnasco, Matteo Ferrando, Marco Caminati, Alice Bragantini, Francesca Puggioni, Gilda Varricchi, Giovanni Passalacqua and Giorgio Walter Canonica

Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems pp. 571-582

Kory Kreimeyer, David Menschik, Scott Winiecki, Wendy Paul, Faith Barash, Emily Jane Woo, Meghna Alimchandani, Deepa Arya, Craig Zinderman, Richard Forshee and Taxiarchis Botsis

Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters pp. 583-596

Natasha Larivée, Samy Suissa, Janie Coulombe, Vicky Tagalakis and Kristian B. Filion

Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals pp. 597-606

Nibu Parameswaran Nair, Leanne Chalmers, Bonnie J. Bereznicki, Colin Curtain, Gregory M. Peterson, Michael Connolly and Luke R. Bereznicki

The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis pp. 607-614

Leàn Rolfes, Florence Hunsel, Laura Linden, Katja Taxis and Eugène Puijenbroek

Impact of Safety-Related Regulations on Codeine Use in Children: A Quasi-Experimental Study Using Taiwan’s National Health Insurance Research Database pp. 615-627

Chih-Wan Lin, Ching-Huan Wang, Wei-I Huang, Wei-Ming Ke, Pi-Hui Chao, Wen-Wen Chen and Fei-Yuan Hsiao

Patient Reporting in the EU: Analysis of EudraVigilance Data pp. 629-645

Marin Banovac, Gianmario Candore, Jim Slattery, Francois Houÿez, David Haerry, Georgy Genov and Peter Arlett

Volume 40, issue 6, 2017

Medicines Save, Medicines Kill pp. 457-459

Joel Lexchin

Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice pp. 461-464

Elisabetta Poluzzi, Emanuel Raschi, Igor Diemberger and Fabrizio De Ponti

Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death pp. 465-474

Raymond L. Woosley, Klaus Romero, Craig W. Heise, Tyler Gallo, Jared Tate, Raymond David Woosley and Sophie Ward

Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan pp. 475-482

Yasuko Inokuma

Evaluation of ‘SAEFVIC’, A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia pp. 483-495

Hazel J. Clothier, Nigel W. Crawford, Melissa Russell, Heath Kelly and Jim P. Buttery

Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals pp. 497-503

Andreas Schick, Kathleen L. Miller, Michael Lanthier, Gerald Dal Pan and Clark Nardinelli

The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone–Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case–Control Study pp. 505-515

Kathrin Jobski, Bianca Kollhorst, Edeltraut Garbe and Tania Schink

A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms pp. 517-530

Cheng Leng Chan, Pei San Ang and Shu Chuen Li

Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study pp. 531-542

Aaron S. Kesselheim, Sarah A. McGraw, Sara Z. Dejene, Paula Rausch, Gerald J. Dal Pan, Brian M. Lappin, Esther H. Zhou, Jerry Avorn and Eric G. Campbell

Volume 40, issue 5, 2017

Antenatal Exposure and Diseases in the Offspring: The Role of Big Data pp. 363-364

Christoph R. Meier and Susan S. Jick

Causality Assessment in Pharmacovigilance: Still a Challenge pp. 365-372

I. Ralph Edwards

Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger? pp. 373-386

Rashmi R. Shah

Sensitivity of the UK Clinical Practice Research Datalink to Detect Neurodevelopmental Effects of Medicine Exposure in Utero: Comparative Analysis of an Antiepileptic Drug-Exposed Cohort pp. 387-397

R. A. Charlton, A. McGrogan, J. Snowball, L. M. Yates, A. Wood, J. Clayton-Smith, W. H. Smithson, J. L. Richardson, N. McHugh, S. H. L. Thomas, G. A. Baker and R. Bromley

Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS pp. 399-408

Susan Colilla, Elad Yom Tov, Ling Zhang, Marie-Laure Kurzinger, Stephanie Tcherny-Lessenot, Catherine Penfornis, Shang Jen, Danny S. Gonzalez, Patrick Caubel, Susan Welsh and Juhaeri Juhaeri

Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study pp. 409-418

Tim Schutte, Jelle Tichelaar, Michael O. Reumerman, Rike Eekeren, Leàn Rolfes, Eugène P. Puijenbroek, Milan C. Richir and Michiel A. Agtmael

Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study pp. 419-430

Tim W. A. Schoenmakers, Martina Teichert, Michel Wensing and Peter A. G. M. Smet

Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification pp. 431-441

Igho J. Onakpoya, Carl J. Heneghan and Jeffrey K. Aronson

Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study pp. 443-455

Sieta T. Vries, Lisa Wong, Alastair Sutcliffe, François Houÿez, Carmen Lasheras Ruiz and Peter G. M. Mol

Volume 40, issue 4, 2017

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns pp. 273-283

Raymond A. Tetteh, Barbara A. Yankey, Edmund T. Nartey, Margaret Lartey, Hubert G. M. Leufkens and Alexander N. O. Dodoo

Digitalis Use and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis pp. 285-292

Chen Zhang, Shao-Hua Xie, Bingfei Xu, Shi Lu and Pian Liu

Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports pp. 293-303

Zahra Anita Trippe, Bruno Brendani, Christoph Meier and David Lewis

Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases pp. 305-315

Carmen Ferrajolo, Katia M. C. Verhamme, Gianluca Trifirò, Geert W. ‘t Jong, Gino Picelli, Carlo Giaquinto, Giampiero Mazzaglia, Bruno H. Stricker, Francesco Rossi, Annalisa Capuano and Miriam C. J. M. Sturkenboom

Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts pp. 317-331

Carrie E. Pierce, Khaled Bouri, Carol Pamer, Scott Proestel, Harold W. Rodriguez, Hoa Le, Clark C. Freifeld, John S. Brownstein, Mark Walderhaug, I. Ralph Edwards and Nabarun Dasgupta

Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention pp. 333-341

Nancy A. Brandenburg, Robert Bwire, John Freeman, Florence Houn, Paul Sheehan and Jerome B. Zeldis

Signal Detection Based on Time to Onset Algorithm in Spontaneous Reporting System of China pp. 343-350

Tianyi Zhang, Xiaofei Ye, Xiaojing Guo, Guizhi Wu, Yongfang Hou, Jinfang Xu, Wentao Shi, Tiantian Zhu, Yuan Zhang, Xinji Zhang, Jiaqi Song and Jia He

Diverging Conclusions from the Same Meta-Analysis in Drug Safety: Source of Data (Primary Versus Secondary) Takes a Toll pp. 351-358

Guillermo Prada-Ramallal, Bahi Takkouche and Adolfo Figueiras

Comment on: “Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France” pp. 359-360

Alain Braillon

Authors’ Reply to Alain Braillon’s Comment on “Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France’’ pp. 361-362

Marine Auffret, Julien Labreuche, Alain Duhamel, Sylvie Deheul, Olivier Cottencin, Régis Bordet, Sophie Gautier and Benjamin Rolland

Volume 40, issue 3, 2017

Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery pp. 191-199

Andrew Bate, Jürgen Beckmann, Alexander Dodoo, Linda Härmark, Kenneth Hartigan-Go, Anna Hegerius, Marie Lindquist, Eugène Puijenbroek, Marco Tuccori and Ulrich Hagemann

Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading? pp. 201-210

Hengameh H. Raissy and H. William Kelly

Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity? pp. 211-228

Rashmi R. Shah

Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis pp. 229-240

Rafail Angelos Kotronias, Chun Shing Kwok, Chun Wai Wong, Tim Kinnaird, Azfar Zaman and Mamas A. Mamas

Effect of Medications for Gastric Acid-Related Symptoms on Total Motile Sperm Count and Concentration: A Case–Control Study in Men of Subfertile Couples from the Netherlands pp. 241-248

Nicole A. Huijgen, Hedwig J. Goijen, John M. Twigt, Annemarie G. M. G. J. Mulders, Jan Lindemans, Gert R. Dohle, Joop S. E. Laven and Régine P. M. Steegers-Theunissen

Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study pp. 249-255

Beatrice Nardone, Sara Majewski, Ashley S. Kim, Tina Kiguradze, Estela M. Martinez-Escala, Rivka Friedland, Ahmad Amin, Anne E. Laumann, Beatrice J. Edwards, Alfred W. Rademaker, Mary C. Martini and Dennis P. West

Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France pp. 257-262

Marine Auffret, Julien Labreuche, Alain Duhamel, Sylvie Deheul, Olivier Cottencin, Régis Bordet, Sophie Gautier and Benjamin Rolland

The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis pp. 263-272

Mei-Sing Ong, Karen L. Olson, Laura Chadwick, Chunfu Liu and Kenneth D. Mandl

Volume 40, issue 2, 2017

Generating Evidence of Clinical Outcomes of Drug–Drug Interactions pp. 101-103

Katsiaryna Bykov and Joshua J. Gagne

Active Surveillance of Follow-on Biologics: A Prescription for Uptake pp. 105-108

Ameet Sarpatwari, Joshua J. Gagne, Nicole L. Levidow and Aaron S. Kesselheim

Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child pp. 109-113

Luc M. Hondeghem and Noël H. Logghe

Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk? pp. 115-119

Edoardo Mannucci and Matteo Monami

The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis pp. 121-132

Fatma Etwel, Lauren H. Faught, Michael J. Rieder and Gideon Koren

Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data pp. 133-144

Andreas D. Meid, Anna Medem, Dirk Heider, Jürgen-Bernhard Adler, Christian Günster, Hanna M. Seidling, Renate Quinzler, Hans-Helmut König and Walter E. Haefeli

Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010–May 2016 pp. 145-152

Pedro Moro, Jane Baumblatt, Paige Lewis, Janet Cragan, Naomi Tepper and Maria Cano

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study pp. 153-167

Marten A. Lantinga, Hedwig M. A. D’Agnolo, Niek F. Casteleijn, Johan W. Fijter, Esther Meijer, Annemarie L. Messchendorp, Dorien J. M. Peters, Mahdi Salih, Edwin M. Spithoven, Darius Soonawala, Folkert W. Visser, Jack F. M. Wetzels, Robert Zietse, Joost P. H. Drenth and Ron T. Gansevoort

Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin pp. 169-181

John D. Seeger, Katsiaryna Bykov, Dorothee B. Bartels, Krista Huybrechts and Sebastian Schneeweiss

Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter" pp. 183-185

Emilie Jouanjus, Michel Mallaret, Joëlle Micallef, Camille Ponté, Anne Roussin and Maryse Lapeyre-Mestre

Authors’ Reply to Jouanjus and Colleagues’ Comment on “Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter” pp. 187-188

Abeed Sarker, Dan Malone and Graciela Gonzalez

Erratum to: Association Between Statin Use and Bell’s Palsy: A Population-Based Study pp. 189-189

Shih-Han Hung, Li-Hsuan Wang, Herng-Ching Lin and Shiu-Dong Chung

Volume 40, issue 1, 2017

On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database pp. 1-2

Jonathan S. Schildcrout, Joshua C. Denny and Dan M. Roden

The Harms of Antipsychotic Drugs: Evidence from Key Studies pp. 3-14

Thomas J. Moore and Curt D. Furberg

Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature pp. 15-36

Dominic Way, Hortense Blazsin, Ragnar Löfstedt and Frederic Bouder

Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines pp. 37-47

Josep Pane, Preciosa M. Coloma, Katia M. C. Verhamme, Miriam C. J. M. Sturkenboom and Irene Rebollo

Vancomycin-Induced Thrombocytopenia: A Narrative Review pp. 49-59

Mehdi Mohammadi, Zahra Jahangard-Rafsanjani, Amir Sarayani, Molouk Hadjibabaei and Maryam Taghizadeh-Ghehi

Proton Pump Inhibitors and Risk of Rhabdomyolysis pp. 61-64

Scott J. Duncan and Colin W. Howden

Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients pp. 65-80

Grace Juyun Kim, Soo Youn Lee, Ji Hye Park, Brian Y. Ryu and Ju Han Kim

Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase® pp. 81-90

Rebecca E. Chandler, Kristina Juhlin, Jonas Fransson, Ola Caster, I. Ralph Edwards and G. Niklas Norén

The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies pp. 91-100

Elisabetta Patorno, Joshua J. Gagne, Christine Y. Lu, Kevin Haynes, Andrew T. Sterrett, Jason Roy, Xingmei Wang and Marsha A. Raebel